New drugmakers could soon offer ‘£20-a-month’ Ozempic-style weight-loss jabs

Firm Novo Nordisk’s global patent is set to expire in parts of the world from early 2026, allowing cut-price ‘own-label’ versions of Wegovy and Ozempic to be sold, according to reports...

Redirecting to full article...